(Q37698956)

22 August 2017

0 references

1 reference

title

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis (English)

1 reference

22 August 2017

arterial hypertension

0 references

0 references

0 references

1 reference

Vishal Ranpura

1

1 reference

22 August 2017

Bhargava Pulipati

2

1 reference

22 August 2017

David Chu

3

1 reference

22 August 2017

Xiaolei Zhu

4

1 reference

22 August 2017

Shenhong Wu

5

1 reference

22 August 2017

25 February 2010

1 reference

Journal of Clinical Hypertension

22 August 2017

1 reference

22 August 2017

23

1 reference

22 August 2017

5

1 reference

22 August 2017

460-468

1 reference

Molecular mechanisms of tumor angiogenesis and tumor progression

22 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Managing patients treated with bevacizumab combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Bevacizumab, bleeding, thrombosis, and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Early breast cancer therapy and cardiovascular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Management of hypertension in angiogenesis inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

Selecting and appraising studies for a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

7 January 2021

Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

7 January 2021

Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

7 January 2021

Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

7 January 2021

Gastrosplenic fistula from Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

7 January 2021

Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.25

7 January 2021

Identifiers

DOI

10.1038/AJH.2010.25

1 reference

22 August 2017

1 reference